Carcinoid Tumor and Neuroendocrine Tumors
Contents (8)
Neuroendocrine tumors (NETs) are rare, heterogeneous malignancies arising from enterochromaffin cells distributed throughout the gastrointestinal tract, pancreas, and other endocrine tissues. Carcinoid tumors represent the most common type of NET and are defined by their capacity to secrete bioactive amines and peptides, though many remain asymptomatic. NETs account for approximately 0.5% of all gastrointestinal malignancies with an incidence of 2–5 per 100,000 person-years, though autopsy series suggest true prevalence may be 10-fold higher due to occult disease. The clinical significance extends beyond their rarity; NETs present unique diagnostic challenges due to nonspecific symptoms and variable biologic behavior, ranging from indolent tumors discovered incidentally to aggressive malignancies with distant metastases at presentation. Understanding NET biology, classification by location and grade, and the distinction between functioning and nonfunctioning tumors is critical for boards and clinical practice, as management and prognosis differ substantially by these factors.
Origin and Cellular Differentiation
NETs derive from neuroendocrine cells (also called enterochromaffin or enteroendocrine cells) distributed throughout the gastrointestinal tract, lungs, and pancreas. These cells possess neurosecretory granules containing bioactive compounds. The tumors exhibit variable differentiation; well-differentiated NETs show preserved neuroendocrine morphology with low mitotic rates, whereas poorly differentiated neuroendocrine carcinomas display high-grade cytology and rapid growth. This spectrum of differentiation fundamentally determines biologic behavior and is the basis for current grading systems (Grade 1–3 based on Ki-67 proliferation index and mitotic count).
Molecular Pathogenesis - Genetic Alterations
Unlike common carcinomas, NETs lack frequent TP53 or KRAS mutations in early-stage disease. Instead, MEN1 gene inactivation is the most common alteration, occurring in ~25% of gastroenteropancreatic NETs (GEP-NETs), particularly pancreatic NETs. MEN1 encodes menin, a tumor suppressor regulating chromatin remodeling and transcriptional regulation; loss disrupts cell cycle control. Other recurrent alterations include DAXX and ATRX mutations (chromatin remodelers, ~40% of pancreatic NETs), which promote tumor progression and correlate with shorter survival. PTEN loss and mTOR pathway activation have been documented and provide therapeutic targets. In pulmonary NETs, other genetic landscapes predominate, with multiple endocrine neoplasia type 1 (MEN1) being less frequent. These molecular differences explain why NETs can occur sporadically or as part of hereditary syndromes (MEN1, MEN4, NF1, VHL, TSC).
Peptide and Amine Secretion - Functional Consequences
Serotonin (5-hydroxytryptamine, 5-HT) is the prototypical secreted product, synthesized from dietary tryptophan via tryptophan hydroxylase and aromatic amino acid decarboxylase. Serotonin causes mesenteric and hepatic venous vasoconstriction, increases intestinal motility, and triggers platelet aggregation. When NET hepatic metastases bypass first-pass hepatic metabolism (allowing serotonin to enter systemic circulation), carcinoid syndrome develops. Other secreted products include substance P and tachykinins (causing diarrhea through cAMP-mediated intestinal secretion and increased motility), kallikrein (producing vasoactive bradykinins), and histamine (causing flushing and bronchoconstriction). Pancreatic NETs may secrete gastrin (causing severe peptic ulcer disease, Zollinger-Ellison syndrome), insulin (causing hypoglycemia), VIP (causing severe diarrhea and hypokalemia, VIPoma syndrome), or glucagon (causing hyperglycemia and necrolytic dermatitis). The quantity of hormone secreted, rate of hepatic metabolism, and proximity of tumor to draining venous routes all influence whether a "silent" NET remains asymptomatic or produces florid syndromes.
Carcinoid Syndrome Pathophysiology
In the normal individual, GI serotonin is metabolized by monoamine oxidase in the liver. Hepatic metastases bypass this first-pass metabolism, allowing serotonin to enter systemic circulation. Circulating serotonin acts on 5-HT2 and 5-HT3 receptors on vascular smooth muscle and peripheral nerves, causing facial flushing, diarrhea, bronchoconstriction, and right-sided cardiac valvulopathy. Serotonin also stimulates fibroblast proliferation via TGF-β signaling, leading to fibrotic plaques on tricuspid and pulmonary valves (resulting in stenosis and regurgitation). Substance P and tachykinins potentiate flushing and diarrhea through enhanced intestinal secretion. The metabolite 5-hydroxyindoleacetic acid (5-HIAA), generated by monoamine oxidase breakdown of serotonin, accumulates and is excreted in urine, serving as a diagnostic marker.
Tumor Growth and Microenvironment
NETs demonstrate slow growth rates compared to adenocarcinomas, partly due to preserved neuroendocrine differentiation and expression of somatostatin receptors, which have growth-inhibitory effects. The tumor microenvironment includes abundant immune infiltrates (lymphocytes, often beneficial) and extensive vascularity, enabling hematogenous spread. Well-differentiated tumors may remain confined to the submucosa or lamina propria for extended periods; however, those penetrating the muscularis propria acquire metastatic potential. Size itself is prognostically relevant: tumors <1 cm have ~2% lymph node metastasis risk, whereas those >2 cm have >50% metastatic risk.
Metastatic Pathophysiology
Liver is the most common site of metastatic disease (~40–50% of patients at diagnosis), followed by regional lymph nodes and bone. Hepatic involvement is particularly significant because it allows secreted hormones to bypass first-pass metabolism, unmasking functional syndromes. The liver's high vascularity and slow growth rate of NETs facilitate occult metastases. Peritoneal and distant (lung, bone, brain) metastases can occur but are less common with low-grade disease.
Sporadic Neuroendocrine Tumors (Most Common)
The majority of NETs (~90%) arise sporadically without identified genetic predisposition. Exact etiology remains unclear; chronic inflammation, repeated mucosal injury, or hypergastrinemia (in gastric NETs associated with chronic atrophic gastritis) may contribute. Risk increases with age, with peak incidence in the 6th–7th decades.
Multiple Endocrine Neoplasia Type 1 (MEN1) - Syndromic NETs
MEN1 accounts for ~25–30% of pancreatic NETs and ~10–20% of gastric NETs. MEN1 is caused by MEN1 gene mutations on chromosome 12q13 and is inherited in an autosomal dominant pattern. Affected individuals develop gastroenteropancreatic NETs (often multifocal), parathyroid adenomas, and anterior pituitary adenomas. In MEN1, gastric NETs are typically associated with chronic hypergastrinemia from gastrinomas (Zollinger-Ellison syndrome) or chronic atrophic gastritis with elevated gastrin. Pancreatic NETs in MEN1 are more likely to be non-functional than sporadic tumors. Early genetic screening and surveillance with imaging and hormonal studies is critical in MEN1 families.
Chronic Atrophic Gastritis and Hypergastrinemia
Chronic autoimmune gastritis (associated with pernicious anemia), Helicobacter pylori infection, or long-term proton pump inhibitor (PPI) use elevates gastrin levels, promoting growth of gastric type 1 NETs (the most common gastric NET subtype, ECL-cell derived). These tumors rarely metastasize but can progress to more aggressive types; gastric pH >4 with documented hypergastrinemia and gastric NETs should prompt investigation for gastrinoma (Zollinger-Ellison syndrome).
Other Hereditary Syndromes
- MEN4 (CDKN1B mutations)
- Neurofibromatosis Type 1 (NF1) with increased risk of pancreatic NETs and pulmonary carcinoids
- Von Hippel-Lindau (VHL) disease with renal and pancreatic NETs
- Tuberous Sclerosis Complex (TSC) with increased NET prevalence
Immunosuppression
Human immunodeficiency virus (HIV)-infected individuals have modestly increased NET incidence, possibly related to immune dysregulation.
Prior Chemotherapy and Radiation
History of chemotherapy or radiation therapy may increase subsequent NET risk, though this association remains incompletely characterized.
Asymptomatic / Incidental Discovery
Approximately 40–50% of NETs are discovered incidentally during endoscopy, imaging, or surgery for unrelated reasons. Small gastric or rectal NETs confined to the submucosa often remain clinically silent for extended periods. Biochemical markers may be elevated (e.g., elevated 24-hour urinary 5-HIAA) without clinical syndrome.
Carcinoid Syndrome (Symptomatic Functional Tumors)
Carcinoid syndrome occurs in only 10–15% of NET patients, predominantly those with hepatic metastases or primary mesenteric tumors. Classic tetrad includes:
- Facial Flushing: Sudden onset, bright red, typically affecting the face and neck, lasting seconds to minutes. Triggered by alcohol, spicy food, stress, or spontaneously. Pathophysiology: serotonin and tachykinins cause cutaneous vasodilation via 5-HT2 receptors. Over time, chronic flushing can progress to permanent telangiectasia and facial edema.
- Diarrhea: Occurs in ~75% of carcinoid syndrome cases, ranging from mild to incapacitating (up to 10–20 bowel movements daily). Mechanism: serotonin and substance P increase cAMP in intestinal epithelial cells, enhancing fluid secretion and increasing motility. Diarrhea is often refractory to standard antidiarrheal agents but responds to somatostatin analogs.
- Bronchoconstriction: Presents as wheezing, dyspnea, or bronchospasm, occurring in ~8% of carcinoid syndrome patients. More common in foregut NETs (gastric, pancreatic). Mechanism: serotonin and other mediators directly constrict bronchial smooth muscle. Can be severe and life-threatening.
- Right-Sided Cardiac Valvulopathy: Chronic serotonin exposure and local TGF-β signaling induce proliferation of endocardial fibroblasts, leading to fibrotic plaques on tricuspid and pulmonary valves. Results in stenosis, regurgitation, or both. Patients develop progressive dyspnea, peripheral edema, and right heart failure. Echocardiography reveals characteristic thickened valves with restricted motion. Left-sided valves are spared (in situ serotonin is inactivated by monoamine oxidase in pulmonary vasculature). Congestive heart failure from carcinoid valvulopathy carries significant morbidity and mortality.
Zollinger-Ellison Syndrome (Gastrin-Secreting NETs)
Gastrin-secreting NETs (gastrinomas) cause severe, refractory peptic ulcer disease and chronic diarrhea. Clinical presentation includes:
- Severe epigastric pain
- Multiple peptic ulcers (often distal duodenum, jejunum—unusual locations)
- Diarrhea (from gastric acid hyperchlorhydria suppressing lipase and damaging intestinal mucosa)
- Diagnosis: fasting serum gastrin >1000 pg/mL or gastrin 100–1000 pg/mL with gastric pH <2
Insulinoma Presentation
Insulin-secreting NETs cause hypoglycemic episodes with Whipple triad: symptoms of hypoglycemia (diaphoresis, palpitations, anxiety, tremor, confusion), documented low blood glucose (<55 mg/dL), and relief with glucose administration. Attacks often occur with fasting or exercise. Diagnosis requires simultaneous low glucose with inappropriately elevated insulin and C-peptide.
VIPoma Presentation
VIP-secreting NETs cause severe, watery diarrhea (>1 L daily), leading to profound hypokalemia, hyponatremia, and dehydration. Classic acronym is WDHA: Watery Diarrhea, Hypokalemia, Achlorhydria (though gastric acid is often preserved). Diagnosis: elevated plasma VIP (>75 pg/mL typically) with secretory diarrhea.
Glucagonoma Presentation
Glucagon-secreting NETs present with hyperglycemia, necrolytic dermatitis (dermatitis, stomatitis, alopecia in characteristic migratory pattern), thromboembolism, and weight loss. Rash typically involves perianal, peroral, and intertriginous areas, reflecting amino acid depletion from hyperglucagonemia.
Non-Functional Tumors
~40–50% of NETs are non-functional (do not cause clinical syndromes). Patients present with:
- Abdominal pain or mass effect from primary or metastatic disease
- Constitutional symptoms: weight loss, fatigue
- Findings from metastatic disease: hepatomegaly, ascites, jaundice
- Anemia from chronic disease or bleeding
Appendiceal and Rectal NETs
Small appendiceal and rectal NETs are often incidental findings on pathology after appendectomy or colonoscopy for other indications. Rectal NETs typically remain asymptomatic; appendiceal NETs may present with appendicitis-like symptoms if large or with bleeding.
Physical Exam Findings
- Hepatomegaly (suggesting hepatic metastases)
- Lymphadenopathy
- Telangiectasia and permanent flushing (chronic carcinoid syndrome)
- Peripheral edema, ascites, elevated JVP (carcinoid heart disease with right heart failure)
- Wheezing (bronchoconstriction)
- Skin rash (necrolytic dermatitis in glucagonoma)
Clinical Suspicion and History
A detailed history focusing on flushing episodes (onset, triggers, duration, associated symptoms), diarrhea pattern and impact, dyspnea/wheezing, and constitutional symptoms is paramount. Ask about family history (MEN1, hereditary syndromes). Differentiate carcinoid syndrome from other causes of flushing (menopause, rosacea, anxiety, medications). History of peptic ulcer disease or refractory gastritis should raise suspicion for gastrinoma.
Biochemical Markers
24-Hour Urinary 5-HIAA:
- Sensitivity: 90% for carcinoid syndrome; lower (~40%) for nonfunctional tumors
- Specificity: ~89%
- Normal value: <8 mg/24 hours (or <40 μmol/24 hours)
- Abnormal value: Typically >8 mg/24 hours in symptomatic carcinoid syndrome; marked elevation (>20 mg/24 hours) strongly suggests significant tumor burden
- Interpretation: Requires 5-HT precursors (tryptophan) adequate in diet; SSRIs and other serotonergic agents can falsely elevate. Patient should avoid bananas, pineapple, walnuts, and other high-serotonin foods for 3 days before collection. Most sensitive diagnostic test for functional NETs but normal in some patients with small tumors or nonfunctional NETs.
Serum Chromogranin A (CgA):
- Normal value: <100 ng/mL (varies by lab; cutoffs 94–120 ng/mL)
- Sensitivity: 60–80% overall; highest for advanced/metastatic NETs
- Specificity: ~80–90%, but can be elevated in proton pump inhibitor use, atrophic gastritis, renal failure, and other neuroendocrine conditions
- Clinical utility: General NET
Immediate stabilisation — carcinoid crisis
- Somatostatin analog (octreotide, IV bolus followed by continuous infusion): first action for flushing, hypotension, and bronchospasm precipitated by anesthesia, tumor manipulation, biopsy, or hepatic embolization. It suppresses release of serotonin and tachykinins from secretory granules rather than blocking their receptors. NCCN Neuroendocrine and Adrenal Tumors guidelines recommend prophylactic octreotide before any procedure in patients with a functional tumor.
- IV fluids and vasopressin or phenylephrine if pressors are required: catecholamines (epinephrine, norepinephrine, dopamine) can paradoxically worsen crisis by stimulating further mediator release from tumor cells.
First-line therapy for established disease
- Long-acting somatostatin analogs (octreotide LAR, lanreotide depot): bind SSTR2/SSTR5, controlling flushing and diarrhea and providing antiproliferative benefit (basis of the PROMID and CLARINET trials). This is the NCCN- and NANETS-endorsed first-line systemic therapy for well-differentiated, somatostatin-receptor-positive disease.
- Proton pump inhibitors at high dose for gastrinoma; diazoxide for insulinoma-related hypoglycemia pending resection.
Escalation / second-line
- Telotristat ethyl: tryptophan hydroxylase inhibitor, added for carcinoid diarrhea refractory to somatostatin analogs.
- Peptide receptor radionuclide therapy (lutetium-177 dotatate): for progressive SSTR-avid midgut NETs (NETTER-1).
- Targeted agents: everolimus (mTOR inhibitor) for GI, lung, and pancreatic NETs; sunitinib for pancreatic NETs.
- Cytotoxic chemotherapy: capecitabine–temozolomide for pancreatic NETs; platinum–etoposide for poorly differentiated neuroendocrine carcinoma, which is treated like small-cell carcinoma.
- Liver-directed therapy: hepatic artery embolization or cytoreductive debulking for dominant hepatic burden.
Definitive/surgical management
- Complete resection is the only cure. Appendiceal NET <1 cm: appendectomy suffices; >2 cm or with mesoappendiceal invasion: right hemicolectomy. Small rectal NETs <1 cm are resected endoscopically. Midgut primaries warrant mesenteric nodal clearance.
- Valve replacement for symptomatic carcinoid heart disease, per ACC/AHA valvular heart disease guidance, ideally after systemic hormonal control.
Avoid: unopposed catecholamines in crisis, and unprotected anesthesia induction without somatostatin coverage.
Emergencies
- Carcinoid crisis: massive mediator release during anesthesia, tumor manipulation, embolization, or biopsy. Signals itself as profound flushing, hypotension refractory to fluids, tachyarrhythmia, and bronchospasm. Treat with somatostatin analog; catecholamines worsen it.
- Ulcer perforation or hemorrhage in Zollinger-Ellison syndrome: unremitting acid hypersecretion; heralded by peritonitis or hematemesis with ulcers in unusual distal duodenal/jejunal locations.
- Severe hypokalemia with arrhythmia in VIPoma and neuroglycopenic coma in insulinoma are metabolic emergencies.
Disease-related
- Carcinoid heart disease: serotonin-driven TGF-β fibroblast proliferation produces plaque-like tricuspid and pulmonary valve thickening; signalled by rising JVP, ascites out of proportion to edema, and a holosystolic murmur augmented by inspiration. Left-sided involvement should prompt search for a bronchial primary or right-to-left shunt.
- Mesenteric fibrosis and desmoplasia: fibrotic retraction of the small-bowel mesentery causes bowel obstruction or mesenteric ischemia — classic for ileal primaries and often disproportionate to a tiny tumor.
- Pellagra: tryptophan diverted into serotonin synthesis depletes niacin precursor; look for dermatitis, diarrhea, dementia and glossitis. Treat with niacin supplementation.
- Hepatic replacement by metastases with liver failure; bone metastases with pain.
Treatment-related
- Somatostatin analogs: gallstones (inhibited gallbladder contraction and cholecystokinin release), steatorrhea and fat-soluble vitamin deficiency (pancreatic enzyme suppression), hyperglycemia, and bradycardia. Cholecystectomy is often performed at the time of any planned abdominal surgery.
- Peptide receptor radionuclide therapy: renal tubular uptake causing nephrotoxicity (mitigated by amino acid co-infusion) and delayed myelosuppression/myelodysplastic syndrome.
- Everolimus: stomatitis, hyperglycemia, and non-infectious pneumonitis — new dyspnea with ground-glass opacities.
- Sunitinib: hypertension, hand-foot syndrome.
- Hepatic embolization: post-embolization syndrome (fever, pain, transaminitis) and precipitated carcinoid crisis.
- Carcinoid syndrome implies hepatic metastases for a midgut primary, because portal drainage otherwise delivers serotonin to hepatic monoamine oxidase. Exceptions that bypass the portal system: bronchial, ovarian, and retroperitoneal primaries — a stem with flushing and a normal liver should push you toward these.
- Best next diagnostic step in suspected carcinoid syndrome is 24-hour urinary 5-HIAA; the best imaging step to localize and stage is Ga-68 DOTATATE PET/CT, which has supplanted the older octreotide scan (Octreoscan).
- Right-sided valve fibrosis only — tricuspid regurgitation and pulmonary stenosis. Serotonin is inactivated in the pulmonary vasculature, sparing left-sided valves. Left-sided disease is the classic distractor and implies a bronchial primary or a patent foramen ovale.
- Pellagra is the association examiners love: tryptophan shunted toward serotonin leaves too little for niacin, producing dermatitis, diarrhea, and dementia in a patient already flushing.
- Octreotide before anything invasive. Any stem in which anesthesia, biopsy, or embolization triggers refractory hypotension is carcinoid crisis; the answer is a somatostatin analog, not epinephrine.
- Chromogranin A is a poor screening test in anyone on a PPI — PPIs, atrophic gastritis, and renal failure all raise it. Do not choose it over 5-HIAA for a flushing patient.
- Foregut NETs may have a normal 5-HIAA because they lack aromatic L-amino acid decarboxylase and secrete 5-HTP rather than serotonin. A normal 5-HIAA does not exclude a NET.
- Ki-67 index and mitotic count, not size alone, drive grade and therapy; a poorly differentiated neuroendocrine carcinoma is treated with platinum–etoposide, not somatostatin analogs, per NCCN.
- Appendiceal NET <1 cm found incidentally after appendectomy needs no further surgery — the distractor is reflex right hemicolectomy, which is reserved for larger or invasive lesions.